Elite Pharmaceuticals Inc Stock Price, News & Analysis

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) reported significant financial results for the fiscal year ended March 31, 2022. Consolidated revenues grew by 27% to $32.3 million, largely driven by sales of generic Adderall and Naltrexone Tablets. Operating profits increased to $5.1 million, up $3.0 million year-over-year, while net income reached $8.9 million. The company is set to discuss these results in a conference call scheduled for June 30, 2022, at 11:30 AM EDT. For more details, stakeholders are encouraged to submit questions ahead of the call.

Elite Pharmaceuticals has received FDA approval for its generic version of Sabril (Vigabatrin USP) 500 mg powder for solution. This antiepileptic drug is indicated for refractory complex partial seizures, targeting patients with inadequate responses to alternative treatments. Lannett Company holds the exclusive marketing rights in the U.S. and territories, while Elite will manufacture and package the product. The collaboration entails shared profits from product net sales, enhancing Elite's market position in the specialty pharmaceutical sector.

Elite Pharmaceuticals (OTCQB:ELTP) announced it will release its 2022 year-end financial results on June 29, 2022. Following this, a live conference call will be held on June 30, 2022, at 11:30 AM EDT, where management will discuss financial and operational results. Stockholders are encouraged to submit questions prior to the call. Elite Pharmaceuticals specializes in the development of niche generic products and operates a cGMP and DEA registered facility for manufacturing.

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) announced the appointment of Robert Chen, CPA/MPA, as its new Chief Financial Officer (CFO), effective May 16, 2022, succeeding Marc Bregman. Chen, with over 20 years of experience in financial leadership within the life sciences sector, previously held significant roles at notable firms including KBP Biosciences and Novartis. His expertise in financial reporting and operational management is expected to strengthen Elite's executive team and contribute positively to its financial operations.

Elite Pharmaceuticals (OTCQB:ELTP) announced FDA approval for doxycycline hyclate 100 mg tablets, an antibiotic targeting various bacterial infections. This approval was achieved in collaboration with Praxgen Pharmaceuticals. The company specializes in niche generic products and operates a registered facility in Northvale, NJ. The approval could enhance Elite's market presence and revenue potential in the competitive pharmaceutical space.

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) reported a strong performance for the third quarter of fiscal year 2022, ended December 31, 2021. Consolidated revenues reached $9.0 million, up 48% year-over-year, driven by increased sales of Amphetamine IR Tablets and ER Capsules. The company also posted an operating profit of $1.8 million, an increase of $0.8 million compared to the prior year, and net income of $2.3 million. A conference call is scheduled for February 15 at 11:30 AM EST to discuss these results and recent developments.

Elite Pharmaceuticals (OTC PINK:ELTP) will announce its third quarter financial results for the fiscal year 2022 on February 14, 2022. Following the release, management will conduct a live conference call on February 15, 2022, at 11:30 AM EST to review financials and operational updates. Shareholders are encouraged to submit questions prior to the call. Elite Pharmaceuticals specializes in developing niche generic products and operates a cGMP facility in Northvale, NJ.

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) reported second quarter fiscal year 2022 financial results for the period ending September 30, 2021. The company achieved revenues of $8.6 million, reflecting a 16% increase from the previous year, driven by strong sales of Amphetamine IR Tablets and ER Capsules. Operating profits rose to $1.4 million, and net income was $1.8 million. A conference call regarding these results is scheduled for November 16, 2021, at 11:30 AM EST.

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) will release its second quarter financial results for the fiscal year 2022 on November 15, 2021. A live conference call is scheduled for November 16 at 11:30 AM EST, where management will discuss financial and operating results, alongside a business update. Stakeholders are encouraged to submit questions before the call. Elite Pharmaceuticals focuses on developing niche generic products and operates a cGMP facility in Northvale, NJ. For more details, visit www.elitepharma.com.